Gp354 nucleic acids and polypeptides
First Claim
1. An isolated polynucleotide comprising a cDNA sequence that encodes SEQ ID NO:
- 12 or a allelic variant of SEQ ID NO;
12.
4 Assignments
0 Petitions
Accused Products
Abstract
An isolated polynucleotide encoding a novel immunoglobulin superfamily member named GP354 is provided. GP354 has a predicted single membrane spanning domain and five immunoglobulin (Ig) domains in the extracellular portion of the protein. The protein structure and tissue distribution of GP354 indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the pancreas and central nervous system (CNS). Provided by the invention are isolated GP354 related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to GP354, cells which produce such antibodies, and related diagnostic and therapeutic methods.
98 Citations
39 Claims
-
1. An isolated polynucleotide comprising a cDNA sequence that encodes SEQ ID NO:
- 12 or a allelic variant of SEQ ID NO;
12. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 34, 35, 36, 37, 38, 39)
- 12 or a allelic variant of SEQ ID NO;
-
25. A method of identifying a compound that binds a GP354 protein, comprising the steps of:
-
contacting a GP354 protein with a test compound; and
detecting a complex formed by said GP354 protein and said test compound, wherein the presence of said complex indicates that said test compound binds to said GP354 protein.
-
-
26. A method of identifying a compound that modulates the activity of a GP354 protein, comprising the steps of:
-
contacting said GP354 protein with a test compound; and
determining the effect of the test compound on the activity of said GP354 protein, whereas a change of said activity after the contacting step indicates that said test compound modulates the activity of said GP354 protein.
-
- 27. A method of diagnosing a disease condition in a subject, comprising the step of comparing the amount or activity of a GP354 protein in a tissue sample from the subject to that of the GP354 protein in a control sample, wherein a significant difference in the amount or activity of said GP354 protein in said tissue sample relative to control indicates that the subject has a disease condition.
- 30. A method of diagnosing a disease condition in a subject, comprising the step of comparing the amount of a gp354 mRNA in a tissue sample from the subject to that of the gp354 mRNA in a control sample, wherein a significant difference in the amount of the mRNA in said tissue sample relative to control indicates that the subject has a disease condition.
-
33. A diagnostic assay for identifying in a test cell the presence or absence of a genetic lesion or mutation characterized by at least one of:
- (i) aberrant modification or mutation of a gene encoding a GP354 protein, (ii) mis-regulation of a gene encoding a GP354 protein, and (iii) aberrant post-translational modification of a GP354 protein, comprising the steps of;
separately hybridizing nucleic acids from the test cell and from a reference cell that lacks said genetic lesion or mutation with a nucleic acid probe comprising SEQ ID NO;
1, 3, 7, 9 or 11, or a portion thereof having at least 17 nucleotides, under high stringency hybridization conditions; and
separately washing said nucleic acid hybrids under high stringency wash conditions to allow dissociation of the hybrids; and
determining whether said nucleic acid probe dissociates more readily from the nucleic acids of the test cell compared to the nucleic acids of the reference cell.
- (i) aberrant modification or mutation of a gene encoding a GP354 protein, (ii) mis-regulation of a gene encoding a GP354 protein, and (iii) aberrant post-translational modification of a GP354 protein, comprising the steps of;
Specification